Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 10/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079521 | 0.87 | FOLH1 (0.40) | PTGER1FOLH1L3MBTL1NPC1MAPT | |
| SCHEMBL6080482 | 0.85 | XDH (0.40) | THRATHRB | |
| SCHEMBL6592161 | 0.79 | MRGPRX4 (0.46) | PTGER1FOLH1CYP1A2L3MBTL1NPC1 | |
| SCHEMBL6079648 | 0.77 | PTGER1 (0.48) | PTGER1FOLH1CYP1A2L3MBTL1NPC1 | |
| SCHEMBL6080525 | 0.76 | PTGER1 (0.46) | PTGER1FOLH1CYP1A2L3MBTL1MAPT | |
| SCHEMBL9785320 | 0.73 | MAPK14 (0.45) | PTGER1FOLH1CYP1A2L3MBTL1THRA | |
| SCHEMBL6080461 | 0.73 | FOLH1 (0.50) | PTGER1FOLH1L3MBTL1NPC1MAPT | |
| SCHEMBL6081012 | 0.73 | THRA (0.43) | PTGER1SMN1; SMN2THRATHRB | |
| SCHEMBL6079972 | 0.72 | MRGPRX4 (0.46) | PTGER1FOLH1CYP1A2L3MBTL1NPC1 | |
| SCHEMBL6080445 | 0.72 | MAPT (0.47) | PTGER1FOLH1CYP1A2L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | PTGER1 1819/4885FOLH1 3307/4885CYP1A2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.